10/08/2023 - Press release
A team from the Hospital del Mar Research Institute has, for the first time, detected fetal DNA in the olfactory neuroepithelium of women who have given birth to a boy. A new study will now be launched, which will also analyze female fetal DNA. The team of researchers has been able to confirm that women with depression had much lower levels of cells from newborns than those who were not suffering from this disorder. This discovery paves the way to studying the DNA exchange between the mother and the fetus during pregnancy as a factor that protects women against depression, as well as its relationship with other psychiatric disorders.
28/07/2023 - Press release
Cannabis use disorder (CUD) affects over 14 million individuals in the US.? Despite the urgent need, there are no FDA-approved medications to treat CUD; behavioral treatments have shown limited benefit. AEF0117 is the first of a new pharmacologic class, type 1 cannabinoid receptor signaling-specific inhibitors (CB1-SSi), with a unique mechanism of action and greater safety and efficacy than prior generations of CB1 inhibitors.? In a phase 2a clinical study in volunteers with CUD, AEF0117 produced statistically significant reductions in the positive subjective and reinforcing effects of smoked cannabis.
15/06/2023 - Press release
A study published in iScience, spearheaded by the Hospital del Mar Research Institute and the Barcelonaβeta Brain Research Centre, part of the Pasqual Maragall Foundation, validates these tools for monitoring potential sufferers. Data was analysed from 56 volunteers who participated in the PENSA study, designed to determine whether it is possible to slow cognitive decline in stages prior to the onset of dementia through a combination of a lifestyle intervention programme and the consumption of a preparation based on a green tea component. It was possible to monitor the evolution of the cognitive functions of these people much more closely and continuously than with standard tests. This paves the way for the adaptation, practically in real time, of treatments that can be adjusted to changes in cognitive decline.
02/05/23 - Institutional news
The Anti-Doping Laboratory of Catalonia was visited last week by a delegation of the Board of Directors of the Catalan Association of Sports Directors (ACDE). ACDE is an association that brings together leaders, federations and professionals in the world of sport in Catalonia while providing them with the best tools to develop their role and promote excellence in the management and values of sport. The delegation was formed by Pere Sust (President of ACDE), Jordi Durá (Secretary), Francisco Sanahuja, Miquel Torres, Pilar Xifré, Manuel Martínez and Judith Martínez, all of them with extensive and recognized links to Catalan and international sports federations and organizations, and was received by the IMIM management and the Laboratory management. After an introduction of the activities of IMIM and the Laboratory, the attendees visited the Laboratory facilities
23/03/2023 - General information
The Associació Catalana de Gestors Esportius Professionals has recognized the international projection of the Laboratory. The Associació Catalana de Gestors Esportius Professionals (ACGEP) has awarded the Catalonia Prize for Sports Management on a national or international level to the Catalonian Anti-Doping Laboratory of the Hospital del Mar Medical Research Institute. The award recognizes the role of the Laboratory in projecting Catalonia to the world, its professionalism and its contribution to a cleaner sport. It was also highlighted that it is one of the thirty laboratories accredited in the world by the World Anti-Doping Agency to carry out doping controls on athletes, and that it works for clean sport in various national and international events.
23/02/2023 - Institutional news
The Associació Catalana de Dirigents de l'Esport (ACDE) awarded the distinction of Best Professional Leader to Dr. Rosa Ventura Alemany, director of the Anti-Doping Laboratory of Catalonia of the Hospital del Mar Institute of Medical Research. The distinction recognizes her work leading the Laboratory, one of the 30 laboratories accredited by the World Anti-Doping Agency in the world, and as coordinator of the Research Group on doping control in sport. It also recognizes the Laboratory's work in conducting doping controls for the 2018 Mediterranean Games in Tarragona, and in the management of athletes' biological passports. Finally, it recognizes the relevant scientific results achieved in recent years by the Research Group coordinated by Dr. Ventura Alemany.
18/01/2023 - General information
The Integrated Pharmacology and Systems Neurosciences Research Group of the Hospital del Mar Medical Research Institute has just published a study in Neurobiology of Disease, in which it highlights the role of the CDK5 protein as a possible marker of early psychosis. Furthermore, this protein is modulated by cannabis use. This paves the way for possible future treatments based on CDK5 expression.
Més informació "Possible biomarker for early psychosis identified"
20/12/2022 - General information
The Board of Trustees of the Spanish Psychiatry and Mental Health Foundation has chosen Dr. Víctor Pérez, head of the Psychiatry Department of the Hospital del Mar and coordinator of the Mental Health Research Group of the Hospital del Mar Medical Research Institute, as the new president of the organization. This appointment comes after Dr. Perez left his position as president of the executive committee of the Spanish Society of Psychiatry and Mental Health. As the highest representative of the foundation, Dr. Pérez will be responsible for representing the entity, chairing the meetings of its board of trustees and executing the agreements reached. The aim of its activity is to contribute to the knowledge, development and improvement of psychiatry and mental health and the disciplines that are linked to it.
Més informació "Dr. Víctor Pérez will chair the Spanish Foundation of Psychiatry and Mental Health."
02/12/2022 - Press release
The Hospital del Mar Medical Research Institute is leading the study that will evaluate whether a new molecule can be used to improve the cognitive performance of people with Down syndrome. The study is part of the ICOD project for the improvement of cognition in Down syndrome, promoted by the European Union, which is funding a project of this type for the first time. The treatment has already passed the trial phase with volunteers without Down syndrome, which sought to certify the safety and tolerability of the medicine. In this new phase, the safety of the treatment in people with Down syndrome will be validated and the first indications of effectiveness will be obtained. It is estimated that results may be available by mid-2023.
16/11/2022 - Press release
A study led by the Hospital del Mar Medical Research Institute, the Barcelonaβeta Brain Research Centre (BBRC), a research unit from the Pasqual Maragall Foundation, and the University of Gothenburg, has compared the validity of nine biomarkers for the day-to-day diagnosis of Alzheimer's disease in hospital centres. The work involved a cohort of patients from Hospital del Mar with various neurological pathologies. The researchers analysed the presence of nine variants of the Tau protein in blood samples from these people. Some of these blood markers are just as useful for detecting Alzheimer's as those measured in the reference test used, namely the analysis of cerebrospinal fluid obtained by lumbar puncture. Less invasive plasma biomarker determinations than those performed after a lumbar puncture may provide a tool for improving the diagnosis of Alzheimer's disease and determining which individuals should undergo further testing to confirm the diagnosis. The work has been published in the leading journal in this field, Alzheimer's & Dementia.
© Institut Hospital del Mar
d'Investigacions MèdiquesLegal Notice and Privacy Policy | Cookie Policy | Site Index | Accessibility | Find Us | Contact
